AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 7 - (NewsRx.com & NewsRx.net) --
by Michelle Marble, staff medical writer -- Peptide mapping results in discovery of potential anticancer epitopes, researchers in England say.
"The human epithelial mucin MUCI is over-expressed in more than 90% of carcinomas of the breast, ovary, and pancreas as well as in some other tumors, making it a potential target for tumor immunotherapy," wrote L.C. Heukamp and colleagues, Guy's Hospital, London, in the International Journal of Cancer.
"We have identified several MUCI-derived peptides mapping outside the variable number tandem repeat region that comply with the peptide-binding motif for HLA-A*0201 and that become processed into stable major histocompatibility complex-peptide complexes as assessed by in vitro assays."
The researchers conducted their experiments in A2/K-b transgenic mice. They found three peptides, MUC79-87 (TLAPATEPA), MUC167-175 (ALGSTAPPV), and MUC264-272 (FLSFHISNL), that elicited peptide-specific cytotoxic T lymphocyte (CTL) immunity in these mice.
This immunity protected the mice against ...
Source: HighBeam Research, Peptide-Based Vaccine Has Potential.(cancer vaccine)